

Suppl. Fig. 1. Coexpression of p-cortactin and F-actin in 16HBE14o- cells shown by immunofluorescence assays after neutrophil elastase (NE) treatment. **A**) Cells were treated with different doses of NE (0, 25, 50, 100 ng/ml). Scale bar = 50 μm. **B**) Intensity of fluorescence of p-cortactin and F-actin protein expression in different NE-treated group. An independent samples *t*-test was conducted for the statistical analysis, and data were presented as mean ± SD, $n = 3$. $^{*}p < 0.01$ vs. untreated group, $^{\#}p < 0.01$ vs. 25 ng/ml NE-treated group



Suppl. Fig. 2. Immunofluorescence assay of phosphorylated myristoylated alanine-rich C-kinase substrate (p-MARCKS) after neutrophil elastase (NE) treatment. **A**) 16HBE14o- cells were treated with different doses of NE (0, 25, 50, 100 ng/ml). Scale bar = 50 μm. **B**) The intensity of fluorescence of p-MARCKS expression in different NE-treated groups. An independent samples *t*-test was conducted for the statistical analysis, and data were presented as mean ± SD, $n = 3$. $^{*}p < 0.01$ vs. untreated group, $^{\#}p < 0.01$ vs. 25 ng/ml NE-treated group



Suppl. Fig. 3. Immunofluorescence assay of phosphorylated activated CDC42 kinase 1 (p-ACK1) after neutrophil elastase (NE) treatment. **A**) The 16HBE14o- cells were treated with 0, 25, 50, or 100 ng/ml NE, and red fluorescence indicates p-ACK1. Scale bar = 50 μm. **B**) Intensity of fluorescence of p-ACK1 expression in different NE-treated groups. An independent samples *t*-test was conducted for the statistical analysis, and data were presented as mean ± SD, $n = 3$. *$p < 0.01$ vs. untreated group